The University of Rochester's costly legal battle to reap billions of dollars in royalties from a new class of "super aspirin" appeared to be over Monday, after the U.S. Supreme Court refused to hear its claims. The high court denied the school's request for a review of lower court rulings that dismissed its patent infringement claims against the makers of lucrative painkillers known as cox-2 inhibitors, which include Pfizer Inc.'s Celebrex and Merck & Co.'s Vioxx.
November 30, 2004 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Presented by BigVoodoo
Legal professionals from In-House, Private Practice and the Bar work together to overcome challenges facing dispute resolution.
This conference brings together the industry's most influential & knowledgeable real estate executives from the net lease sector.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania with their dedication to law.
We have been retained to identify a highly motivated, business-minded Associate Corporate Counsel with around 2-4 years of transactional exp...
Our client, a national provider of professional liability insurance, has exclusively engaged us in a search for a FP&A Executive who wil...
Our client, a national residential builder and developer, is seeking to hire a real estate attorney (minimum of 5+ years’ of experienc...
GILL & CHAMAS Congratulations to our partner and friend,DAVID H. LANDE, ESQ on his appointment to Judge in the Division of Workers Compensation.
Bennett, Tina mourns the loss of Elizabeth (Libby) Bennett, Esq.
